BONBID-HIE2024

新生儿缺氧缺血性脑病是一种严重的脑功能障碍，每200名新生儿中约有1人受影响。尽管治疗性低温疗法在2005年引入后取得了进展，但仍有许多婴儿预后不佳，35%-50%的婴儿出现不良的神经认知后果。早期识别高风险婴儿和准确评估治疗结果的能力有限，这突显了对早期和准确预后的生物标志物的需求。2023年首次举办的HIE脑MRI挑战赛重点是婴儿脑MRI中的病变分割。今年的MICCAI 2024挑战赛进一步扩展了目标，包括：1) 婴儿脑MRI中的病变分割；2) 使用婴儿脑MRI预测2年后的神经认知结果。新增加的目标具有重要的临床意义。

Hypoxic-ischemic encephalopathy (HIE) in neonates is a severe cerebral dysfunction affecting approximately 1 in 200 newborns. Since the introduction of therapeutic hypothermia in 2005, progress has been made, yet many infants still experience poor prognoses, with 35%–50% suffering from adverse neurocognitive outcomes. The limited capacity to early identify high-risk infants and accurately evaluate treatment outcomes underscores the critical demand for biomarkers that facilitate early and accurate prognostication. The inaugural HIE Brain MRI Challenge was first hosted in 2023, focusing on lesion segmentation in infant brain MRI. The 2024 MICCAI Challenge has further expanded its scope to include two core tasks: 1) lesion segmentation in infant brain MRI; 2) prediction of neurocognitive outcomes at 2 years of age using infant brain MRI. The newly added tasks carry substantial clinical significance.

搜集汇总

背景与挑战

背景概述

BONBID-HIE2024是一个公开的新生儿缺氧缺血性脑病（HIE）脑部MRI数据集，包含133名患者的扩散MRI图像和专家手动标注的病灶信息，用于支持HIE相关小范围弥散性病灶的MRI分割研究。数据集采用CC BY许可，鼓励学术和研究使用。